United Therapeutics Co. (NASDAQ:UTHR) has earned an average rating of “Hold” from the fourteen ratings firms that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $129.56.

A number of equities analysts have issued reports on UTHR shares. Wedbush restated an “outperform” rating on shares of Purple Innovation in a report on Wednesday, May 8th. ValuEngine upgraded China Southern Airlines from a “sell” rating to a “hold” rating in a report on Tuesday, June 11th. Oppenheimer started coverage on in a report on Tuesday, April 9th. They set an “outperform” rating and a $55.00 price target on the stock. UBS Group set a $25.00 price target on Macy’s and gave the stock a “hold” rating in a report on Friday, May 17th. Finally, BidaskClub cut Zebra Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th.

In related news, Director Raymond Dwek sold 3,750 shares of the stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $76.11, for a total value of $285,412.50. Following the transaction, the director now directly owns 3,750 shares in the company, valued at approximately $285,412.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Richard Giltner sold 5,000 shares of the stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $79.05, for a total value of $395,250.00. Following the completion of the transaction, the director now owns 5,000 shares in the company, valued at $395,250. The disclosure for this sale can be found here. 8.20% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its holdings in shares of United Therapeutics by 2.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,088,982 shares of the biotechnology company’s stock valued at $118,583,000 after purchasing an additional 29,427 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of United Therapeutics by 0.8% in the fourth quarter. Bank of America Corp DE now owns 93,345 shares of the biotechnology company’s stock valued at $10,165,000 after purchasing an additional 706 shares during the last quarter. Amundi Pioneer Asset Management Inc. increased its holdings in shares of United Therapeutics by 137.1% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 64,134 shares of the biotechnology company’s stock valued at $6,984,000 after purchasing an additional 37,086 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of United Therapeutics by 6.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 11,060 shares of the biotechnology company’s stock valued at $1,204,000 after purchasing an additional 630 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of United Therapeutics by 11.6% in the fourth quarter. Legal & General Group Plc now owns 112,631 shares of the biotechnology company’s stock valued at $12,265,000 after purchasing an additional 11,664 shares during the last quarter. Institutional investors own 96.32% of the company’s stock.

NASDAQ:UTHR opened at $77.60 on Wednesday. The firm’s 50 day moving average price is $78.44. The company has a debt-to-equity ratio of 0.45, a current ratio of 7.19 and a quick ratio of 6.84. United Therapeutics has a fifty-two week low of $74.31 and a fifty-two week high of $130.00.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share for the quarter, missing analysts’ consensus estimates of $2.64 by ($13.96). The firm had revenue of $362.70 million for the quarter, compared to analyst estimates of $335.72 million. United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. The business’s revenue for the quarter was down 6.8% compared to the same quarter last year. During the same period in the prior year, the company posted $3.76 EPS. On average, sell-side analysts expect that United Therapeutics will post -5.03 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Featured Article: What does the Producer Price Index (PPI) tell investors?

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.